PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy.

Programmed death-ligand 1 (PD-L1) plays a central role in immune evasion by tumors, making it a crucial target for cancer immunotherapy. While current anti-PD-L1 therapies have shown promise, they face several clinical limitations, such as suboptimal efficacy and resistance. Recent advancements in PD-L1-targeted molecules, including bifunctional small-molecule inhibitors and protein degradation strategies, are revolutionizing cancer treatment. These novel approaches target PD-L1 at multiple levels, disrupting tumor immune escape and enhancing antitumor immunity. Bifunctional inhibitors target both PD-L1 and additional immune or non-immune pathways, providing improved tumor penetration and overcoming resistance mechanisms. Protein degradation technologies, such as PROTACs, facilitate targeted PD-L1 degradation via proteasomal or lysosomal pathways, offering more durable therapeutic effects. Furthermore, innovations like bioorthogonal chemistry and lysosome-targeting technologies promise more precise drug delivery and reduced systemic toxicity. This review highlights the latest developments in PD-L1 modulation, explores their mechanisms of action, and discusses their therapeutic potential, paving the way for next-generation cancer immunotherapies.